Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration.
Adolescent
Adult
Aged
Aged, 80 and over
Albendazole
/ therapeutic use
Animals
Child
Child, Preschool
Cross-Sectional Studies
Elephantiasis, Filarial
/ complications
Endemic Diseases
Female
Humans
Ivermectin
/ therapeutic use
Lymphedema
/ drug therapy
Male
Mali
/ epidemiology
Mass Drug Administration
Middle Aged
Morbidity
Prevalence
Public Health
Withholding Treatment
Wuchereria bancrofti
Young Adult
Active and passive case detection
Clinical investigation
Distribution
Lymphedema
Mali
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
15 Jan 2020
15 Jan 2020
Historique:
received:
15
07
2019
accepted:
08
01
2020
entrez:
17
1
2020
pubmed:
17
1
2020
medline:
9
4
2020
Statut:
epublish
Résumé
Lymphedema is a public health problem in countries with lymphatic filariasis (LF) including Mali. We studied the epidemiology and clinical presentation of lymphedema in three previously LF-endemic health districts of Mali after at least five consecutive rounds of mass drug administration (MDA) with albendazole and ivermectin. From 2016 to 2018, we used passive and active case finding methods to identify lymphedema cases in three health districts with high pre-MDA LF prevalence: Kolondieba (66%), Bougouni (44%) and Kolokani (34%). Three hundred and thirty nine cases of lymphedema were identified, 235 (69.32%) through active case finding. Their median age was 56 years (range 2-90) and 286 (84.36%) were women. Lymphedema was reported in 226 (78.5%) people aged 41 years and older compared to 73 (21.5%) people below the age of 41 years (Chi Health districts in Mali with the highest pre-MDA LF prevalences had the highest prevalence of lymphedema. Efforts to actively identify lymphedema cases should be scaled up in previous LF-endemic areas, and should be supplemented by a morbidity management and disability prevention plan at the peripheral health system level.
Sections du résumé
BACKGROUND
BACKGROUND
Lymphedema is a public health problem in countries with lymphatic filariasis (LF) including Mali. We studied the epidemiology and clinical presentation of lymphedema in three previously LF-endemic health districts of Mali after at least five consecutive rounds of mass drug administration (MDA) with albendazole and ivermectin.
METHODS
METHODS
From 2016 to 2018, we used passive and active case finding methods to identify lymphedema cases in three health districts with high pre-MDA LF prevalence: Kolondieba (66%), Bougouni (44%) and Kolokani (34%).
RESULTS
RESULTS
Three hundred and thirty nine cases of lymphedema were identified, 235 (69.32%) through active case finding. Their median age was 56 years (range 2-90) and 286 (84.36%) were women. Lymphedema was reported in 226 (78.5%) people aged 41 years and older compared to 73 (21.5%) people below the age of 41 years (Chi
CONCLUSION
CONCLUSIONS
Health districts in Mali with the highest pre-MDA LF prevalences had the highest prevalence of lymphedema. Efforts to actively identify lymphedema cases should be scaled up in previous LF-endemic areas, and should be supplemented by a morbidity management and disability prevention plan at the peripheral health system level.
Identifiants
pubmed: 31941448
doi: 10.1186/s12879-020-4777-6
pii: 10.1186/s12879-020-4777-6
pmc: PMC6964034
doi:
Substances chimiques
Ivermectin
70288-86-7
Albendazole
F4216019LN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Subventions
Organisme : FIC NIH HHS
ID : D43 TW008652
Pays : United States
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases (US)
ID : Z01-AI001063
Organisme : USAID Global Development Alliance
ID : AID-OAA-G-14-000008
Références
N Engl J Med. 2012 May 31;366(22):2136-7
pubmed: 22646649
Int J Dermatol. 2016 May;55(5):563-70
pubmed: 26518364
PLoS Negl Trop Dis. 2012;6(3):e1574
pubmed: 22448294
J Am Acad Dermatol. 2017 Dec;77(6):1009-1020
pubmed: 29132848
PLoS Negl Trop Dis. 2018 Jul 2;12(7):e0006491
pubmed: 29965963
Plast Reconstr Surg. 2011 Jun;127(6):2419-31
pubmed: 21617474
Ann N Y Acad Sci. 2008;1131:147-54
pubmed: 18519968
PLoS Negl Trop Dis. 2016 Feb 05;10(2):e0004424
pubmed: 26849126
PLoS Negl Trop Dis. 2016 Aug 22;10(8):e0004917
pubmed: 27548382
PLoS Negl Trop Dis. 2019 Jan 30;13(1):e0007064
pubmed: 30699120
J Pathol. 1981 Mar;133(3):229-42
pubmed: 7463212
Health Hum Rights. 2018 Jun;20(1):27-40
pubmed: 30008550
Parasit Vectors. 2013 Aug 28;6(1):247
pubmed: 23981378
Trans R Soc Trop Med Hyg. 2007 Apr;101(4):391-7
pubmed: 17112555
Wkly Epidemiol Rec. 2011 Dec 16;86(51-52):581-5
pubmed: 22191103
Lymphat Res Biol. 2013 Sep;11(3):144-8
pubmed: 24044755
PLoS Negl Trop Dis. 2018 Mar 1;12(3):e0006324
pubmed: 29494642
J Vector Borne Dis. 2015 Jun;52(2):111-5
pubmed: 26119541
J Am Acad Dermatol. 2008 Aug;59(2):324-31
pubmed: 18513827
Trans R Soc Trop Med Hyg. 1976;70(4):288-95
pubmed: 1006757
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3319
pubmed: 25412180
Lancet. 2007 Mar 17;369(9565):888-9
pubmed: 17368134